Quantcast

Industry news that matters to you.  Learn more

AmberGen and Mass General License Two Novel Autoantigen Biomarkers for Autoimmune Liver Disease to INOVA Diagnostics

Two novel autoantigen biomarkers for the autoimmune liver disease Primary Biliary Cirrhosis (PBC), discovered by AmberGen, Inc., in collaboration with the Massachusetts General Hospital (MGH), were exclusively licensed to INOVA Diagnostics, Inc., part of the Werfen Group, and a world-leader in clinical assays for autoimmune disease. Discovery of these biomarkers was made possible by the use of AmberGen’s proprietary proteomic biomarker discovery pipeline and funded by an Advanced Technology Small Business Innovation Research (SBIR) grant to AmberGen from the National Institute of Allergy and Infectious Disease, part of the National Institutes of Health. Following the work done by AmberGen and MGH, the biomarkers where subjected to further clinical validation by INOVA.

Plasma Biomarkers in Liver Cancer Refine Stratification of Patient Risk

According to an Internal Medicine News report, data presented at the 2011 Gastrointestinal Cancers Symposium at the American Society of Clinical Oncology meeting on gastrointestinal cancers in January sponsored by the American Society of Clinical Oncology suggests that a simple blood test may improve on systems conventionally used to estimate prognosis in patients with hepatocellular carcinoma.

CXCL10 is a Negative Prognostic Biomarker of Viral Clearance in Chronic HCV Patients

French researchers recently analyzed chronic hepatitis C virus (HCV) patients to identify plasma biomarkers for response to therapy. They identified CXCL10 as a negative prognostic biomarker of viral clearance.

Ariana Pharma Enters Viral Hepatitis Partnership with Bio-Rad, INSERM and Beaujon Hospital

Ariana Pharma, a leader in decision support tools and services to accelerate the development and optimal use of drugs and biomarker discovery, announces today that it has entered into a partnership to improve the diagnosis and prognosis of chronic hepatitis.

Ariana is collaborating with AP-HP (Beaujon Hospital) and INSERM joined center of excellence for viral hepatitis and Bio-Rad France to apply its novel technology to the discovery of new biomarkers. The Hepachronix project pools their collective expertise to identify, develop and market new tools for the early diagnosis of fibrosis and for the prognosis of resistance to treatment. Diagnostics specialist Bio-Rad leads this 3-year-project.